Pembrolizumab plus Lenvatinib as First-line Therapy for Advanced Non-clear-cell Renal Cell Carcinoma (KEYNOTE-B61)
16594
post-template-default,single,single-post,postid-16594,single-format-standard,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-5.7,vc_responsive
 

Pembrolizumab plus Lenvatinib as First-line Therapy for Advanced Non-clear-cell Renal Cell Carcinoma (KEYNOTE-B61)

Home > Blogs  > Pembrolizumab plus Lenvatinib as First-line Therapy for Advanced Non-clear-cell Renal Cell Carcinoma (KEYNOTE-B61)

16 Aug Pembrolizumab plus Lenvatinib as First-line Therapy for Advanced Non-clear-cell Renal Cell Carcinoma (KEYNOTE-B61)

Posted at 05:43h in Blogs by

In the KEYNOTE-B61 phase 2, single-arm study, patients with previously untreated stage IV non-clear-cell renal cell carcinoma treated with pembrolizumab plus lenvatinib showed a confirmed objective response (49%; 95% CI 41-57), including confirmed complete response (6%) and partial response (44%). The most common Grade 3-4 treatment-related adverse events were hypertension (23%), proteinuria (4%), and stomatitis (4%). (Albiges L, et al. Lancet Oncol. August, 2023)

#oncologyresearch #clinicalresearch #clinicaldevelopment

No Comments

Sorry, the comment form is closed at this time.